- Report
- May 2026
- 194 Pages
Global
From €5150EUR$5,850USD£4,455GBP
- Report
- May 2026
- 126 Pages
Global
From €5150EUR$5,850USD£4,455GBP
- Report
- May 2026
- 126 Pages
Global
From €5150EUR$5,850USD£4,455GBP
- Report
- May 2026
- 291 Pages
Global
From €5150EUR$5,850USD£4,455GBP
- Report
- May 2026
- 183 Pages
Global
From €5150EUR$5,850USD£4,455GBP
- Report
- May 2026
- 183 Pages
Global
From €5150EUR$5,850USD£4,455GBP
- Report
- May 2026
- 193 Pages
Global
From €5150EUR$5,850USD£4,455GBP
- Report
- May 2026
- 277 Pages
Global
From €5150EUR$5,850USD£4,455GBP
- Report
- May 2026
- 590 Pages
Global
From €5150EUR$5,850USD£4,455GBP
- Report
- January 2026
- 180 Pages
Global
From €3961EUR$4,500USD£3,427GBP
- Report
- January 2026
- 180 Pages
Global
From €3961EUR$4,500USD£3,427GBP
- Report
- January 2026
- 182 Pages
Global
From €3961EUR$4,500USD£3,427GBP
- Report
- January 2026
- 180 Pages
Global
From €3961EUR$4,500USD£3,427GBP
- Report
- January 2026
- 193 Pages
Global
From €3121EUR$3,545USD£2,700GBP
€3468EUR$3,939USD£3,000GBP
- Report
- August 2025
- 199 Pages
Global
From €3121EUR$3,545USD£2,700GBP
€3468EUR$3,939USD£3,000GBP
- Report
- August 2025
- 186 Pages
Global
From €3121EUR$3,545USD£2,700GBP
€3468EUR$3,939USD£3,000GBP
- Report
- August 2025
- 195 Pages
Global
From €3121EUR$3,545USD£2,700GBP
€3468EUR$3,939USD£3,000GBP
- Report
- May 2026
- 279 Pages
Global
From €5150EUR$5,850USD£4,455GBP
- Report
- May 2026
- 139 Pages
Global
From €5150EUR$5,850USD£4,455GBP
- Report
- May 2026
- 484 Pages
Global
From €5150EUR$5,850USD£4,455GBP

The Checkpoint Inhibitors market is a subset of the Oncology Drugs market, which focuses on treatments for cancer. Checkpoint Inhibitors are a type of immunotherapy, which works by blocking certain proteins that act as “checkpoints” in the body’s immune system. By blocking these checkpoints, the body’s immune system is able to recognize and attack cancer cells. This type of therapy has been found to be effective in treating a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer.
The Checkpoint Inhibitors market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Merck, Bristol-Myers Squibb, Roche, AstraZeneca, and Pfizer. Show Less Read more